Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Linkoping – page 12

180 clinical trials in Linkoping, Sweden across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Linkoping at a glance
180
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

180 trials in Linkoping

Open in trial search

Asthma

Not recruiting

Study on the Effectiveness and Safety of AZD4604 for Adults with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

Investigational
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:(2R)-N-[3-(5-Fluoro-2-{[2-Fluoro-3-(Methylsulfonyl)Phenyl]Amino}-4-Pyrimidinyl)-1H-Indol-7-Yl]-3-Methoxy-2-(4-Methyl-1-Piperazinyl)Propanamide-1-Hydroxy-2-Naphthoic Acid
  • Sponsor:AstraZeneca AB

Drug use disorder

Not recruiting

Study on Long-Term Effects of Buprenorphine in Adults with Opioid Use Disorder

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Buprenorphine
  • Sponsor:Indivior Inc.

Cholangitis sclerosing

Not recruiting

Study on Simvastatin for Treating Primary Sclerosing Cholangitis in Patients

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Simvastatin
  • Sponsor:Karolinska University Hospital

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab with Platinum-Based Chemotherapy for Patients with Early-Stage Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Acute myeloid leukaemia

Not recruiting

Study on the Safety and Effectiveness of Adding Hydroxycarbamide to Standard Treatment with Cytarabine and Daunorubicin for Adults with Newly Diagnosed Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Karolinska University Hospital

Hypercholesterolaemia

Not recruiting

Study on Evolocumab for Reducing Cardiovascular Events in Patients with Acute Myocardial Infarction

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Follicle centre lymphoma follicular grade I II - III refractory

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Linkoping

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Groundbreaking studies focusing on atrial fibrillation prevention and treatment of chronic kidney disease with hypertension. Research includes novel therapies for stroke prevention and innovative drug combinations for metabolic conditions.

  • Stroke Prevention Trials
  • Hypertension Management
  • Metabolic Disorders

Current studies evaluate new anticoagulants and combination therapies for better patient outcomes.

02 Oncology Studies

Comprehensive research into various cancer types, including lymphocytic leukemia, testicular cancer, and esophageal carcinoma. Studies focus on optimizing treatment sequences and exploring new therapeutic approaches.

  • Hematological Malignancies
  • Solid Tumors
  • Pediatric Oncology

Investigations include both conventional and innovative treatment strategies.

03 Neurological & Mental Health

Innovative research examining prolonged grief disorder and major depressive disorder. Studies investigate novel therapeutic approaches and hormone effects on decision-making processes.

  • Depression Treatment
  • Behavioral Studies
  • Hormone Research

Research combines pharmacological interventions with behavioral assessments.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.